US bank sees positive risk-reward for AstraZeneca ahead of pivotal heart drug trial

Citi sees the risk-reward balance as favourable for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) ahead of headline results from a pivotal trial of its heart drug Wainua, expected in the third quarter of 2026. Wainua is a TTR-silencer, a drug that suppresses production of a protein called transthyretin (TTR) which can misfold and accumulate in the heart and nerves, causing a progressive condition known as ATTR-cardiomyopathy (ATTR-CM).

Proactive Investors • May 29, 2026

CelLBxHealth signs master services agreement with AstraZeneca

CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the circulating tumour cell (CTC) intelligence company, has signed a master services agreement with AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical group. The deal establishes CelLBxHealth as a qualified service provider to the Anglo-Swedish giant, allowing it to support drug discovery and development through CTC-powered analytics of clinical trial samples using its Parsortix platform.

Proactive Investors • May 29, 2026

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's IMFINZI® (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatment of adult patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC). The approval by the Food and Drug Administration (FDA) is based on positive results from the POTOMAC Phase III trial which were presented at the European Society for Medical Oncology (ESMO) Congress 2025 and s.

Business Wire • May 29, 2026

US FDA extends review of AstraZeneca's experimental breast cancer pill

AstraZeneca ​said on ‌Wednesday ​the ​U.S. Food ⁠and ​Drug Administration ​has extended ​its ​review deadline for ‌its ⁠experimental breast ​cancer ​pill ⁠camizestrant ​to ​assess ⁠additional data.

Reuters • May 27, 2026

FDA Extends Review Time for AZN's Camizestrant Combo in Breast Cancer

AstraZeneca faces a longer FDA review for camizestrant combo in a certain type of first-line breast cancer after regulators request additional data.

Zacks Investment Research • May 27, 2026

How Big Pharma Is Turning Industrial Heat Into A Strategic Asset

Inside a pharmaceutical plant, heat is everywhere—and until recently, almost nobody was paying attention to it.

Forbes • May 26, 2026

AZN, Daiichi's Datroway Wins FDA Nod for Expanded Use in Breast Cancer

AstraZeneca and Daiichi Sankyo get FDA approval for Datroway's expanded use in triple-negative breast cancer treatment.

Zacks Investment Research • May 25, 2026

AZN, Daiichi's Enhertu Gets Positive CHMP Opinion for Solid Tumors

AstraZeneca and Daiichi's Enhertu wins CHMP backing for HER2-positive metastatic solid tumors. The camizestrant combo also gains a positive CHMP nod.

Zacks Investment Research • May 25, 2026

AstraZeneca: 8% Q1 Revenue Growth And Imfinzi/Ultomiris Trial Data Wins

I am initiating AstraZeneca at a "Strong Buy," driven by robust Q1 2026 revenue growth and portfolio momentum. The company's Oncology and Rare Disease segments delivered 16% and 15% growth, powered by IMFINZI and ULTOMIRIS, respectively. Positive phase 3 data for IMFINZI in unresectable HCC and ULTOMIRIS in IgAN unlock significant expansion opportunities.

Seeking Alpha • May 24, 2026

EU regulator recommends positive opinion of AstraZeneca's experimental breast cancer drug

A ​European ‌Medicines ​Agency ​committee said on ⁠Friday it ​has ​adopted a ​positive ​opinion of ‌AstraZeneca's experimental breast ⁠cancer ​drug, ​camizestrant.

Reuters • May 22, 2026